First-Line Panitumumab for Colorectal Cancer

Adding panitumumab to chemotherapy improved outcomes.

The treatment for patients with advanced colorectal cancer (CRC) has progressed, such that median survival now approaches or exceeds 2 years with modern combination chemotherapy. In patients with KRAS wild-type CRC, epidermal growth factor receptor (EGFR)-targeted antibody therapy with either cetuximab or panitumumab as single agents improves survival, and cetuximab plus first-line chemotherapy improves progression-free survival (PFS) and overall survival (OS) as well as antitumor response rate.

Now, industry-supported investigators report the results of the first trial to evaluate first-line chemotherapy with or without panitumumab (the completely humanized monoclonal antibody that targets the EGFR) for advanced CRC. Nearly 1200 patients fr…

Reviewing Author

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo

David H. Ilson, MD, PhD

Disclosures

Consultant/Advisory BoardAstraZeneca; Merck; Taiho; Astellas; Bristol Myers Squibb; Regeneron; Oncolys; Amgen; Daiichi Sankyo